Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Endocrinology

Medications That Weaken Bone: Understanding the Risks

At a Glance

Some medicines—especially steroids, aromatase inhibitors, and androgen deprivation therapy—can weaken bones and raise fracture risk. Early review with a clinician, DXA or spine screening when appropriate, and bone-protective treatment can help reduce harm.

While many medications are vital for treating chronic conditions, some can have the unintended side effect of weakening your skeleton. This occurs through different biological mechanisms—the specific ways a drug interferes with how your body builds or breaks down bone [1][2]. Understanding these risks allows you and your doctor to take protective steps early, often before a fracture occurs.

Glucocorticoids: The Rapid Decline

Glucocorticoids (often called “steroids” like prednisone or dexamethasone) are the most common cause of medication-induced osteoporosis [1]. They cause a rapid decline in bone strength, with the highest risk of fracture occurring within the first 3 to 6 months of treatment [1][3].

The danger with steroids is that they affect bone quality more than they affect bone density alone. You may experience a fracture even if your Dual-energy X-ray Absorptiometry (DXA) scan—the standard test for bone density—still looks relatively “normal” [1][4]. This happens because steroids:

  • Kill bone-building cells: They cause apoptosis (programmed cell death) of osteoblasts, the cells that build new bone, and osteocytes, the cells that maintain bone structure [3][5].
  • Fuel bone-destroying cells: In the early months, they promote the activity of osteoclasts, the cells that break down bone [3].
  • Worsen bone architecture: They damage the microscopic “struts” that provide bone with its internal strength, a change that DXA scans cannot always see [6][7].
  • Cause muscle weakness: Steroids can weaken muscles, which increases your risk of falling and sustaining a fracture [8].

Current guidelines recommend a formal fracture risk assessment as soon as possible for anyone taking 2.5 mg or more of prednisone daily for at least 3 months [9].

Hormonal Therapies: AIs and ADT

Certain cancer treatments work by suppressing the hormones that fuel tumor growth, but these same hormones—estrogen and testosterone—are essential for maintaining bone [10].

  • Aromatase Inhibitors (AIs): Used for breast cancer, these drugs block the body’s ability to make estrogen. This lack of estrogen causes high bone turnover, where the body breaks down bone much faster than it can replace it [11][12]. Significant bone loss can be measured within just 6 months of starting treatment [13].
  • Androgen Deprivation Therapy (ADT): Used for prostate cancer, ADT suppresses testosterone. Since testosterone is converted into estrogen to help maintain bone in men, this therapy removes a critical signal that keeps bones strong [10][14].

For those on these therapies, bone loss is often treated with antiresorptive medications (like bisphosphonates or denosumab) to stabilize bone density [15][16].

PPIs, SSRIs, and Antiepileptics

Other common medications are associated with bone loss, though the evidence is often observational (meaning researchers see a link, but it is affected by other risks and is not as clearly “cause-and-effect” as it is with steroids) [17][18].

  • Proton Pump Inhibitors (PPIs): These acid-blockers (like omeprazole) may alter the absorption of calcium and vitamin D, though this depends on the form (e.g., calcium citrate absorbs well regardless of stomach acid) [19][20]. Long-term use is also linked to hypomagnesemia (low magnesium), which can further weaken bones [19]. You should periodically review with your doctor whether a PPI is still needed.
  • Selective Serotonin Reuptake Inhibitors (SSRIs): Commonly used for depression or anxiety, SSRIs may have direct effects on bone cells [18]. They are also linked to an increased risk of falls, particularly in older adults, which drives up fracture rates [21].
  • Antiepileptic Drugs (AEDs): Older seizure medications can interfere with how your liver processes vitamin D, leading to a deficiency that softens the bone [22]. Newer options like lamotrigine generally appear to have a comparatively safer profile for bone health [22].

Managing Your Risk Safely

It is essential to remember that you should never stop taking these medications abruptly without your doctor’s supervision. Many of these drugs are life-saving or manage severe chronic conditions, and stopping them suddenly can cause dangerous withdrawal symptoms or a relapse of your primary illness.

Instead, the goal is awareness and monitoring. If you are on one of these “culprit” medications, your doctor may recommend:

  1. Baseline screening: A DXA scan and possibly a vertebral fracture assessment (a specialized X-ray of your spine) to see where your bone health stands [9][23].
  2. Supplementation: Ensuring you have adequate calcium and vitamin D intake to support your bones while they are under stress, using lab testing to guide you [24][25].
  3. Dose adjustment: Using the lowest effective dose for the shortest time possible [26].
  4. Protective treatment: Starting a bone-strengthening medication if your risk of fracture is high [24][23].

Common questions in this guide

Which medicines are most strongly linked to drug-induced osteoporosis?
Steroid medicines called glucocorticoids, such as prednisone and dexamethasone, are the most common medication-related cause and can raise fracture risk quickly. Aromatase inhibitors and androgen deprivation therapy also cause bone loss by lowering hormones that help maintain bone. PPIs, SSRIs, and some antiepileptic drugs are associated with bone loss or fractures, but the evidence is less direct.
Can steroids weaken my bones even if my DXA scan looks normal?
Yes. Steroids can damage bone quality and internal structure in ways a DXA scan may not fully capture, so a relatively normal result does not eliminate fracture risk. Risk can be especially high during the first 3 to 6 months, and people taking at least 2.5 mg of prednisone daily for 3 months should ask about a formal fracture-risk assessment.
What tests might I need if my medicine could weaken my bones?
A clinician may recommend a baseline DXA scan and, when appropriate, a vertebral fracture assessment, which is specialized spine imaging. Depending on the medicine, vitamin D or magnesium levels may also be checked. Follow-up timing is individualized based on your medication, dose, duration, and fracture risk.
How can I protect my bones without stopping an important medicine?
Do not stop a prescribed medicine on your own. Your clinician may use the lowest effective dose, review alternatives, ensure adequate calcium and vitamin D, and consider a bone-strengthening medicine such as a bisphosphonate or denosumab when fracture risk is high.
Can breast or prostate cancer hormone treatments weaken bones?
Yes. Aromatase inhibitors used for breast cancer lower estrogen, and androgen deprivation therapy used for prostate cancer suppresses testosterone; both can accelerate bone loss. Clinicians may monitor bone density and consider treatment with a bisphosphonate or denosumab when appropriate.
What should I do if I need to stop denosumab?
Stopping denosumab should be planned with the prescribing clinician because bone density can fall after treatment ends. Your clinician can decide whether another bone-protective medicine and repeat bone-density testing are needed.

Get notified when new evidence is published on drug-induced osteoporosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (26)
  1. 1

    Understanding and Managing Corticosteroid-Induced Osteoporosis.

    Kobza AO, Herman D, Papaioannou A, et al.

    Open access rheumatology : research and reviews 2021; (13()):177-190 doi:10.2147/OARRR.S282606.

    PMID: 34239333
  2. 2

    Drug-induced bone loss: a major safety concern in Europe.

    Nguyen KD, Bagheri B, Bagheri H

    Expert opinion on drug safety 2018; (17(10)):1005-1014 doi:10.1080/14740338.2018.1524868.

    PMID: 30222369
  3. 3

    Glucocorticoid-induced osteoporosis: an update.

    Compston J

    Endocrine 2018; (61(1)):7-16 doi:10.1007/s12020-018-1588-2.

    PMID: 29691807
  4. 4

    Treatment options for glucocorticoid-induced osteoporosis.

    Chiodini I, Merlotti D, Falchetti A, Gennari L

    Expert opinion on pharmacotherapy 2020; (21(6)):721-732 doi:10.1080/14656566.2020.1721467.

    PMID: 32004105
  5. 5

    Pathogenic mechanisms of glucocorticoid-induced osteoporosis.

    Chen M, Fu W, Xu H, Liu CJ

    Cytokine & growth factor reviews 2023; (70()):54-66 doi:10.1016/j.cytogfr.2023.03.002.

    PMID: 36906448
  6. 6

    Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments.

    Lane NE

    Current osteoporosis reports 2019; (17(1)):1-7 doi:10.1007/s11914-019-00498-x.

    PMID: 30685820
  7. 7

    A multiscale study of structural and compositional changes in a natural nanocomposite: Osteoporotic bone with chronic endogenous steroid excess.

    Xi L, Zhang Y, Gupta H, et al.

    Bone 2021; (143()):115666 doi:10.1016/j.bone.2020.115666.

    PMID: 33007528
  8. 8

    Glucocorticoid-induced osteoporosis: novel concepts and clinical implications.

    Hofbauer LC, Compston JE, Saag KG, et al.

    The lancet. Diabetes & endocrinology 2025; (13(11)):964-979 doi:10.1016/S2213-8587(25)00251-7.

    PMID: 41022095
  9. 9

    2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

    Humphrey MB, Russell L, Danila MI, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(12)):2088-2102 doi:10.1002/art.42646.

    PMID: 37845798
  10. 10

    Vitamin D Deficiency in Women with Breast Cancer: A Correlation with Osteoporosis? A Machine Learning Approach with Multiple Factor Analysis.

    de Sire A, Gallelli L, Marotta N, et al.

    Nutrients 2022; (14(8)) doi:10.3390/nu14081586.

    PMID: 35458148
  11. 11

    Aromatase inhibitor-induced bone loss osteosarcopenia in older patients with breast cancer: effects of the RANK/RANKL system's inhibitor denosumab vs. bisphosphonates.

    Casabella A, Paladin F, Bighin C, et al.

    Internal and emergency medicine 2024; (19(8)):2193-2199 doi:10.1007/s11739-024-03725-1.

    PMID: 39095675
  12. 12

    The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

    Ramchand SK, Cheung YM, Yeo B, Grossmann M

    The Journal of endocrinology 2019; (241(3)):R111-R124.

    PMID: 30991355
  13. 13

    Aromatase inhibitor treatment for breast cancer: short-term effect on bone health.

    Erbağ G, Uygun K, Binnetoğlu E, et al.

    Contemporary oncology (Poznan, Poland) 2015; (19(5)):374-7 doi:10.5114/wo.2014.45305.

    PMID: 26793021
  14. 14

    MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone.

    Russell N, Grossmann M

    European journal of endocrinology 2019; (181(1)):R23-R43.

    PMID: 31096185
  15. 15

    AI-related BMD variation in actual practice conditions: A prospective cohort study.

    Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, et al.

    Endocrine-related cancer 2016; (23(4)):303-12 doi:10.1530/ERC-16-0025.

    PMID: 26911377
  16. 16

    New and emerging concepts in the use of denosumab for the treatment of osteoporosis.

    Lewiecki EM

    Therapeutic advances in musculoskeletal disease 2018; (10(11)):209-223 doi:10.1177/1759720X18805759.

    PMID: 30386439
  17. 17

    Osseous implications of proton pump inhibitor therapy: An umbrella review.

    Alanazi AS, Almutairi H, Gupta JK, et al.

    Bone reports 2024; (20()):101741 doi:10.1016/j.bonr.2024.101741.

    PMID: 38348455
  18. 18

    SSRI use and risk of fractures among perimenopausal women without mental disorders.

    Sheu YH, Lanteigne A, Stürmer T, et al.

    Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention 2015; (21(6)):397-403 doi:10.1136/injuryprev-2014-041483.

    PMID: 26113668
  19. 19

    Increased Risk of Fractures and Use of Proton Pump Inhibitors in Menopausal Women: A Systematic Review and Meta-Analysis.

    da Maia TF, de Camargo BG, Pereira ME, et al.

    International journal of environmental research and public health 2022; (19(20)) doi:10.3390/ijerph192013501.

    PMID: 36294082
  20. 20

    Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved.

    Thong BKS, Ima-Nirwana S, Chin KY

    International journal of environmental research and public health 2019; (16(9)) doi:10.3390/ijerph16091571.

    PMID: 31060319
  21. 21

    Impact of prescription drugs on second fragility fractures among US Medicare patients.

    Munson JC, Bynum JPW, Bell JE, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2018; (29(12)):2771-2779 doi:10.1007/s00198-018-4697-0.

    PMID: 30232537
  22. 22

    An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs.

    Miziak B, Chrościńska-Krawczyk M, Czuczwar SJ

    Expert opinion on drug safety 2019; (18(8)):679-689 doi:10.1080/14740338.2019.1625887.

    PMID: 31159612
  23. 23

    Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.

    Waqas K, Lima Ferreira J, Tsourdi E, et al.

    Journal of bone oncology 2021; (28()):100355 doi:10.1016/j.jbo.2021.100355.

    PMID: 33948427
  24. 24

    Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society.

    Paccou J, Yavropoulou MP, Naciu AM, et al.

    European journal of endocrinology 2024; (191(6)):G1-G17 doi:10.1093/ejendo/lvae146.

    PMID: 39556468
  25. 25

    Drug-Induced Osteoporosis.

    Gasser RW, Kocijan R, Zendeli A, Resch H

    Journal of clinical medicine 2026; (15(3)) doi:10.3390/jcm15030993.

    PMID: 41682673
  26. 26

    Medication-induced fractures: Screening and treatment strategies.

    Javed L, Khakwani A, Khan U, Humphrey MB

    The American journal of the medical sciences 2025; (369(1)):1-13 doi:10.1016/j.amjms.2024.08.024.

    PMID: 39214248

This page is for informational purposes only and does not constitute medical advice about medication-related bone loss. Do not stop or change a medicine without speaking with the clinician who prescribed it.

Guide contents drug-induced osteoporosis
Research & Literature
02 Symptoms and Warning Signs